EXHIBIT 4.1 STOCK PURCHASE AGREEMENT This Agreement is made as of _________________, by and between Hollis-Eden Pharmaceuticals, Inc., a Delaware corporation with its principal office at 9333 Genesee Avenue, Suite 110, San Diego, California 92121 (the...Stock Purchase Agreement • May 14th, 1999 • Hollis Eden Pharmaceuticals Inc /De/ • Pharmaceutical preparations • California
ARTICLE I DEFINITIONSEscrow Agreement • September 14th, 2001 • Hollis Eden Pharmaceuticals Inc /De/ • Pharmaceutical preparations • Delaware
LICENSE AGREEMENTLicense Agreement • December 24th, 1996 • Initial Acquisition Corp • Blank checks • Washington
EMPLOYMENT AGREEMENTEmployment Agreement • February 10th, 1997 • Initial Acquisition Corp • Blank checks • California
Exhibit 10.17 HOLLIS-EDEN PHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement ("Agreement") is effective as of ________________, by and between Hollis-Eden Pharmaceuticals, Inc., a Delaware corporation (the "Company"), and...Indemnification Agreement • September 14th, 2001 • Hollis Eden Pharmaceuticals Inc /De/ • Pharmaceutical preparations • Delaware
EXHIBIT 10.16 NEITHER THIS WARRANT NOR THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT" OR ANY OTHER APPLICABLE STATE SECURITIES LAWS. NEITHER THIS WARRANT NOR THE SHARES...Hollis Eden Pharmaceuticals Inc /De/ • September 14th, 2001 • Pharmaceutical preparations
andRights Agreement • November 24th, 1999 • Hollis Eden Pharmaceuticals Inc /De/ • Pharmaceutical preparations
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 8th, 2010 • Harbor BioSciences, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of June 7, 2010, between Harbor Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
EXHIBIT 10.7 AMENDMENT TO CONSULTING AGREEMENT Effective March 12, 2001 (the "Effective Date"), Hollis-Eden Pharmaceuticals, Inc., a Delaware corporation (the "Company"), William H. Tilley ("Tilley") and JacMar/Viking, L.L.C., a Delaware limited...Consulting Agreement • July 8th, 2002 • Hollis Eden Pharmaceuticals Inc /De/ • Pharmaceutical preparations
Harbor BioSciences, Inc. and American Stock Transfer and Trust Company, LLC as Rights Agent Second Amended and Restated Rights Agreement Dated as of July 29, 2011 (original Rights Agreement dated as of November 15, 1999)Rights Agreement • August 3rd, 2011 • Harbor BioSciences, Inc. • Pharmaceutical preparations • Delaware
This Second Amended and Restated Rights Agreement (“Agreement”), is entered into on July 29, 2011 and is an amendment and restatement of the Rights Agreement dated as of November 15, 1999, as previously amended on October 13, 2009, between HARBOR BIOSCIENCES, INC., a Delaware corporation (the “Company”), and AMERICAN STOCK TRANSFER AND TRUST COMPANY, LLC (“Rights Agent”).
RESEARCH, DEVELOPMENT AND OPTION AGREEMENTOption Agreement • December 24th, 1996 • Initial Acquisition Corp • Blank checks
AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • May 15th, 1997 • Hollis Eden Pharmaceuticals Inc /De/ • Blank checks
ARTICLE I DEFINITIONSAdoption Agreement • December 6th, 1999 • Hollis Eden Pharmaceuticals Inc /De/ • Pharmaceutical preparations
period, not less than three (3) Trading Days, to review the proposed Registration Statement or any amendment thereto, prior to filing with the Commission, and the Company shall provide the Purchaser with copies of any comment letters received from the...Registration Rights Agreement • September 14th, 2001 • Hollis Eden Pharmaceuticals Inc /De/ • Pharmaceutical preparations • New York
BY AND AMONGAgreement and Plan of Merger • December 24th, 1996 • Initial Acquisition Corp • Blank checks • Delaware
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 26th, 2003 • Hollis Eden Pharmaceuticals Inc /De/ • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of February 25, 2003, among Hollis-Eden Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the purchasers identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 3rd, 2003 • Hollis Eden Pharmaceuticals Inc /De/ • Pharmaceutical preparations • Delaware
This Registration Rights Agreement (this “Agreement”) is made and entered into as of June 19, 2003, among Hollis-Eden Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the investors signatory hereto (each such investor is a “Investor” and all such investors are, collectively, the “Investors”).
INCENTIVE STOCK OPTIONIncentive Stock Option • December 24th, 1996 • Initial Acquisition Corp • Blank checks
RECITALSTechnology Assignment Agreement • February 4th, 2000 • Hollis Eden Pharmaceuticals Inc /De/ • Pharmaceutical preparations • California
PAYROLL SUPPORT PROGRAM EXTENSION AGREEMENTExtension Agreement • April 1st, 2021 • Harbor Diversified, Inc. • Pharmaceutical preparations • New York
The Department of the Treasury (Treasury) hereby provides Payroll Support (as defined herein) under Subtitle A of Title IV of Division N of the Consolidated Appropriations Act, 2021. The Signatory Entity named above, on behalf of itself and its Affiliates (as defined herein), agrees to comply with this Agreement and applicable Federal law as a condition of receiving Payroll Support. This Signatory Entity and its undersigned authorized representatives acknowledge that a materially false, fictitious, or fraudulent statement (or concealment or omission of a material fact) in connection with this Agreement may result in administrative remedies as well as civil and/or criminal penalties.
Exhibit 4.4 FORM OF STOCK AND WARRANT PURCHASE AGREEMENT Hollis-Eden Pharmaceuticals, Inc. 9333 Genesee Avenue, Suite 200 San Diego, California 92121 The undersigned (the "Investor") hereby confirms its agreement with you as follows: 1. This Stock...Stock and Warrant Purchase Agreement • December 21st, 2001 • Hollis Eden Pharmaceuticals Inc /De/ • Pharmaceutical preparations • California
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 26th, 2003 • Hollis Eden Pharmaceuticals Inc /De/ • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made and entered into as of February 25, 2003, among Hollis-Eden Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the purchasers signatory hereto (each such purchaser is a “Purchaser” and all such purchasers are, collectively, the “Purchasers”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 14th, 2003 • Hollis Eden Pharmaceuticals Inc /De/ • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of February 25, 2003, among Hollis-Eden Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the purchasers identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
STOCK PURCHASE WARRANT To Purchase Shares of Common Stock of Hollis-Eden Pharmaceuticals, Inc.Stock Purchase • March 14th, 2003 • Hollis Eden Pharmaceuticals Inc /De/ • Pharmaceutical preparations
THIS STOCK PURCHASE WARRANT CERTIFIES that, for value received, (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after February 25, 2003 (the “Initial Exercise Date”) and on or prior to the close of business on the fourth anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Hollis-Eden Pharmaceuticals, Inc., a corporation incorporated in the State of Delaware (the “Company”), up to shares (the “Warrant Shares”) of Common Stock, par value $0.001 per share, of the Company (the “Common Stock”). The purchase price of one share of Common Stock (the “Exercise Price”) under this Warrant shall be $ [$6.17/$6.71], subject to adjustment hereunder. The Exercise Price and the number of Warrant Shares for which the Warrant is exercisable shall be subject to adjustment as provided herein. Capitalized terms used and not otherwise defined
HOLLIS-EDEN, INC. 3807 N.E. 127th Circle Vancouver, Washington 98686Placement Agent Agreement • December 24th, 1996 • Initial Acquisition Corp • Blank checks • California
NEITHER THESE SECURITIES NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER...Hollis Eden Pharmaceuticals Inc /De/ • March 14th, 2003 • Pharmaceutical preparations
THIS DEBENTURE is one of a series of duly authorized and issued debentures of Hollis-Eden Pharmaceuticals, Inc., a Delaware corporation, having a principal place of business at 4435 Eastgate Mall, Suite 400, San Diego, CA 92121(the “Company”), designated as its 7.5% Convertible Debentures, due February 25, 2006 in the aggregate principal amount of $10,000,000 (the “Debentures”).
COMMON STOCK PURCHASE WARRANT To Purchase Shares of Common Stock of HOLLIS-EDEN PHARMACEUTICALS, INC.Common Stock Purchase Warrant • February 2nd, 2006 • Hollis Eden Pharmaceuticals Inc /De/ • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after August , 2006 (the “Initial Exercise Date”) and on or prior to the close of business on the fourth year anniversary of the date hereof (the “Termination Date”) but not thereafter, to subscribe for and purchase from Hollis-Eden Pharmaceuticals, Inc., a Delaware corporation (the “Company”), up to shares (the “Warrant Shares”) of Common Stock, par value $0.01 per share, of the Company (the “Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
iii) Provided that at the time of exercise the Company's Common Stock is publicly traded and quoted regularly in the Wall Street Journal, payment by delivery of already-owned shared of Common Stock, held for the period required to avoid a charge to...Nonstatutory Stock • July 8th, 2002 • Hollis Eden Pharmaceuticals Inc /De/ • Pharmaceutical preparations
LICENSE AGREEMENTLicense Agreement • March 31st, 2011 • Harbor BioSciences, Inc. • Pharmaceutical preparations • Hong Kong
THIS LICENSE AGREEMENT (the “Agreement”) is by and between HARBOR BIOSCIENCES, INC., a Delaware corporation (the “Licensor”) having offices at 9171 Towne Centre Drive, Suite 180, San Diego, California 92122, and CHINA INSTITUTE OF PHARMACEUTICAL INDUSTRY a Beijing corporation operating under the law of the People’s Republic of China (the “Licensee”) having offices at 1320 Beijing Road (W), Shanghai, P.R. China.
1 EXHIBIT 10.1 STOCK AND WARRANT PURCHASE AGREEMENTStock and Warrant Purchase Agreement • May 12th, 1998 • Hollis Eden Pharmaceuticals Inc /De/ • Blank checks • Delaware
HOLLIS EDEN PHARMACEUTICALS UNIT WARRANTHollis Eden Pharmaceuticals Inc /De/ • July 8th, 2002 • Pharmaceutical preparations • Delaware
PAYROLL SUPPORT PROGRAM 3 AGREEMENT3 Agreement • March 30th, 2022 • Harbor Diversified, Inc. • Air transportation, scheduled • New York
The Department of the Treasury (Treasury) hereby provides Payroll Support (as defined herein) under section 7301 of the American Rescue Plan Act of 2021. The Signatory Entity named above, on behalf of itself and its Affiliates (as defined herein), agrees to comply with this Agreement and applicable Federal law as a condition of receiving Payroll Support. The Signatory Entity and its undersigned authorized representatives acknowledge that a materially false, fictitious, or fraudulent statement (or concealment or omission of a material fact) in connection with this Agreement may result in administrative remedies as well as civil and/or criminal penalties.
STOCK PURCHASE AGREEMENTStock Purchase Agreement • November 8th, 2006 • Hollis Eden Pharmaceuticals Inc /De/ • Pharmaceutical preparations • New York
THIS STOCK PURCHASE AGREEMENT is dated November 7, 2006 (this “Agreement”), between the undersigned (“Purchaser”) and Hollis-Eden Pharmaceuticals, Inc., a Delaware corporation (the “Company”), whereby the parties agree as follows:
4,000,000 Shares HOLLIS-EDEN PHARMACEUTICALS, INC. Common Stock PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • November 8th, 2006 • Hollis Eden Pharmaceuticals Inc /De/ • Pharmaceutical preparations • New York
Hollis-Eden Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to certain investors (collectively, the “Investors”) up to an aggregate of 4,000,000 shares (the “Shares”) of the Company’s Common Stock, par value $0.01 per share (the “Common Stock”). Each Investor shall also receive a warrant, in the form of Exhibit A attached hereto, to purchase up to a number of shares of the Company’s Common Stock (the “Warrant Shares”) equal to 20% of the Shares purchased by such Investor, at an exercise price equal to $8.75 per share, exercisable beginning six months after issuance and on or prior to the fourth anniversary of issuance (the “Warrants”). The Shares, the Warrant and the Warrant Shares (collectively, the “Securities”) have been registered on a registration statement on Form S-3, File No. 333-135095 (the “Registration Statement”), which has been declared effective by the Securities and Exchange Commission (“SEC”), and remains effective as of the dat
EMPLOYMENT AGREEMENTEmployment Agreement • April 1st, 2021 • Harbor Diversified, Inc. • Pharmaceutical preparations • Wisconsin
This EMPLOYMENT AGREEMENT is made and entered into as of January 1, 2021, by and between Air Wisconsin Airlines LLC, a Delaware limited liability company (the “Company”), and Liam Mackay (the “Executive” and, together with the Company, collectively, the “Parties”).
